Efficacy and Safety of Valsartan 160 mg Plus Hydrochlorothiazide 25 mg Once a Day in Patients With Slight Hypertension and Target Organ Damage.

Trial Profile

Efficacy and Safety of Valsartan 160 mg Plus Hydrochlorothiazide 25 mg Once a Day in Patients With Slight Hypertension and Target Organ Damage.

Completed
Phase of Trial: Phase IV

Latest Information Update: 24 Feb 2013

At a glance

  • Drugs Valsartan/hydrochlorothiazide (Primary)
  • Indications Hypertension; Left ventricular hypertrophy
  • Focus Therapeutic Use
  • Most Recent Events

    • 28 Jan 2009 Actual end date changed from May 2008 to Dec 2008 as reported by ClinicalTrials.gov.
    • 28 Jan 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Jun 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top